Cupressus Nootkatensis

by | Mar 20, 2018 | Cupressus Nootkatensis

How Can We Help?
You are here:
< Back

Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hypertrophy which acts as a selective α1-adrenergic receptor antagonist or alpha-1 blocker.[1]

Synthesis

The reaction of 1-naphthol (1) with epichlorohydrin (2) in the presence of alkali gives the epoxide (3). Alkylation of the piperazine derivative (4) yields naftopidil.[2][3][4]

See also

References

  1. ^ Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, et al. (January 2011). "[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication]". Hinyokika Kiyo. Acta Urologica Japonica. 57 (1): 7–13. PMID 21304253.
  2. ^ US patent 3997666, Witte EC, Stach K, Thiel M, Sponer G, Roesch E, "1-[3-(Naphth-1-yloxy)-2-hydroxypropvl]-piperazine compounds and therapeutic compositions", issued 1976-12-14, assigned to Boehringer Mannheim GmbH 
  3. ^ Pujala B, Chakraborti AK (May 2007). "Zinc(II) perchlorate hexahydrate catalyzed opening of epoxide ring by amines: applications to synthesis of (RS)/(R)-propranolols and (RS)/(R)/(S)-naftopidils". The Journal of Organic Chemistry. 72 (10): 3713–3722. doi:10.1021/jo062674j. PMID 17411096.
  4. ^ "Naftopidil". Pharmaceutical Substances. Thieme. Retrieved 2024-07-12.
Categories
Table of Contents